Corporate News
Therma Bright Provides Update on FDA EUA Application Process For AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
Toronto, Ontario–(Newsfile Corp. – June 2, 2022) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of the smart-enabled AcuVid™ COVID-19 Rapid Antigen
Therma Bright to Submit Application to Health Canada for Approval of its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
Toronto, Ontario–(Newsfile Corp. – May 10, 2022) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), a progressive medical device technology company, is pleased
Therma Bright Submits AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Application for U.S. Food & Drug Administration’s Emergency Use Authorization (EUA)
V.THRM | 1 minute agoToronto, Ontario–(Newsfile Corp. – March 29, 2022) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its
Therma Bright Recognized In 2022 TSX Venture 50 Top Performing Stocks
V.THRM | 4 hours ago Toronto, Ontario–(Newsfile Corp. – February 24, 2022) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of
Therma Bright Receives Patent for a Device for Applying a Topical Treatment from U.S. Patent & Trademark Office (USPTO)
V.THRM | 2 hours ago Toronto, Ontario–(Newsfile Corp. – February 23, 2022) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of
Therma Bright Announces CAD$6 Million Private Placement with Institutional Investors
V.THRM | 1 hour ago Toronto, Ontario–(Newsfile Corp. – February 16, 2022) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of
Therma Bright’s AcuVid(TM) U.S. Clinical Performance Study Successfully Exceeds U.S. Food & Drug Administration’s Emergency Use Authorization Requirements
V.THRM | 5 hours ago Toronto, Ontario–(Newsfile Corp. – February 15, 2022) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of
Therma Bright Provides Update on U.S. Clinical Performance Study
Toronto, Ontario–(Newsfile Corp. – January 20, 2022) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19
Therma Bright AcuVid(TM) COVID-19 Rapid Antigen Saliva Test’s Antibodies Successfully Detect the COVID-19 Omicron B.1.1.529 Variant
Toronto, Ontario–(Newsfile Corp. – December 16, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen
Therma Bright to Begin AcuVid(TM) U.S. Clinical Performance Study with Receipt of IRB Conditional Approval
Toronto, Ontario–(Newsfile Corp. – November 12, 2021) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19
Therma Bright Provides Update for its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
Toronto, Ontario–(Newsfile Corp. – October 4, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), a progressive medical device technology company and developer
Therma Bright’s AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Successfully Detects the COVID-19 Delta Variant Strain
Toronto, Ontario–(Newsfile Corp. – July 8, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva
Therma Bright Provides Update on FDA EUA Application Process For AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
Toronto, Ontario–(Newsfile Corp. – June 2, 2022) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of the smart-enabled AcuVid™ COVID-19 Rapid Antigen
Therma Bright to Submit Application to Health Canada for Approval of its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
Toronto, Ontario–(Newsfile Corp. – May 10, 2022) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), a progressive medical device technology company, is pleased
Therma Bright Submits AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Application for U.S. Food & Drug Administration’s Emergency Use Authorization (EUA)
V.THRM | 1 minute agoToronto, Ontario–(Newsfile Corp. – March 29, 2022) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its
Therma Bright Recognized In 2022 TSX Venture 50 Top Performing Stocks
V.THRM | 4 hours ago Toronto, Ontario–(Newsfile Corp. – February 24, 2022) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of
Therma Bright Receives Patent for a Device for Applying a Topical Treatment from U.S. Patent & Trademark Office (USPTO)
V.THRM | 2 hours ago Toronto, Ontario–(Newsfile Corp. – February 23, 2022) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of
Therma Bright Announces CAD$6 Million Private Placement with Institutional Investors
V.THRM | 1 hour ago Toronto, Ontario–(Newsfile Corp. – February 16, 2022) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of
Therma Bright’s AcuVid(TM) U.S. Clinical Performance Study Successfully Exceeds U.S. Food & Drug Administration’s Emergency Use Authorization Requirements
V.THRM | 5 hours ago Toronto, Ontario–(Newsfile Corp. – February 15, 2022) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of
Therma Bright Provides Update on U.S. Clinical Performance Study
Toronto, Ontario–(Newsfile Corp. – January 20, 2022) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19
Therma Bright AcuVid(TM) COVID-19 Rapid Antigen Saliva Test’s Antibodies Successfully Detect the COVID-19 Omicron B.1.1.529 Variant
Toronto, Ontario–(Newsfile Corp. – December 16, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen
Therma Bright to Begin AcuVid(TM) U.S. Clinical Performance Study with Receipt of IRB Conditional Approval
Toronto, Ontario–(Newsfile Corp. – November 12, 2021) – Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19
Therma Bright Provides Update for its AcuVid(TM) COVID-19 Rapid Antigen Saliva Test
Toronto, Ontario–(Newsfile Corp. – October 4, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), a progressive medical device technology company and developer
Therma Bright’s AcuVid(TM) COVID-19 Rapid Antigen Saliva Test Successfully Detects the COVID-19 Delta Variant Strain
Toronto, Ontario–(Newsfile Corp. – July 8, 2021) – Therma Bright Inc. (TSXV: THRM) (“Therma” or the “Company”), developer of its smart-enabled AcuVid™ COVID-19 Rapid Antigen Saliva
